Opinion: Isolated in Uganda: How Covid-19 evacuations highlight unfairness of global health partnerships
Patients gasping for air in hospital hallways, trailers serving as makeshift morgues, emergency medical tents…
Category: policy
How Nancy Pelosi almost killed drug pricing reform
WASHINGTON — The White House stunned health care experts last month when it declared it was…
STAT+: Here’s how Biden can address high drug prices, without help from Congress
WASHINGTON — If President Biden wants major pharmaceutical industry reforms, he may have to achieve…
Opinion: My company is developing new antibiotics. My resistant infection showed me we need them now
I biked to work in a rainstorm one day in October 2019. As a longtime…
STAT+: Biden abandons his push to lower drug prices
WASHINGTON — The White House is abandoning every single policy idea aimed at lowering prescription…
STAT+: Key Senate committee considers a carveout for small biotech companies in drug pricing reforms
WASHINGTON — A key Senate panel is seriously considering a new policy that would soften…
STAT+: Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?
WASHINGTON — As Democrats design a way to use the government’s leverage to lower drug…
In a new policy proposal, Biden presses Congress to let Medicare negotiate drug prices
President Biden on Thursday took his most concrete action to date on prescription drug prices,…
STAT+: Vulnerable Senate Democrats escalate a push for Medicare to negotiate drug prices
WASHINGTON — Five of the most vulnerable Democrats in the Senate on Tuesday publicly renewed…
STAT+: For the first time ever, Lander’s White House science office will have an entire wing dedicated to health
WASHINGTON — Eric Lander, the renowned genomics researcher, has kept a low profile in his…
STAT+: Senate Democrats eye drug pricing policies to fund $3.5 trillion budget deal
WASHINGTON — Senate Democrats intend to include several drug pricing policies in their $3.5 trillion…
Are pharma mergers bad for biotech?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: Washington’s antitrust push could limit Amazon, Google’s health care ambitions
WASHINGTON — Washington is abuzz with an ambitious new antitrust effort to rein in the…
Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug
WASHINGTON — Former health secretary Donna Shalala called for a federal investigation into the Food…
Opinion: The PASTEUR Act can help win the war against superbugs
Look no further than the coronavirus pandemic to see an immediate and high-profile example of…
STAT+: Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs
WASHINGTON — Sen. Ron Wyden (D-Ore.), the influential chair of the Senate Finance Committee, is…
The lonely quest to create a commission to investigate Covid-19
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm
WASHINGTON — Biogen’s expecting to make billions from its newly approved Alzheimer’s drug Aduhelm. But…
STAT+: BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights
WASHINGTON — Everyone wants to know whether Michelle McMurry-Heath, the newly minted president of the…
STAT+: Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates
WASHINGTON — Sen. Chuck Grassley’s voice boomed through the Senate hearing room — it sounded…
Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval
Following the Food and Drug Administration’s polarizing authorization of the Alzheimer’s therapy Aduhelm on Monday,…
Opinion: Restore a better balance to public-private funding of biomedical research
The pharmaceutical industry says that if the U.S. reduces the astronomical drug prices paid by…
California could become first state to mandate biosecurity screening by mail-order DNA companies
California lawmakers on Thursday will vote on a bill that would require the state’s growing…
Opinion: Beyond a symbolic gesture: What’s needed to turn the IP waiver into Covid-19 vaccines
The Biden administration’s announcement to support an intellectual property (IP) waiver for Covid-19 vaccines was…
Opinion: Make drug companies partners — not adversaries — to expand global Covid-19 vaccine access
The Biden administration’s announcement that it would support waiving patent protections for Covid-19 vaccines to…
Opinion: STAT+: The many benefits of expanding the reach of state all-payer claims databases
Appointments to the newly created State All Payer Claims Databases Advisory Committee in March were…
Former Google CEO Schmidt says AI ‘will have its biggest impact’ in health care
For the myriad applications of artificial intelligence, Eric Schmidt, the onetime Google CEO, sees one…
STAT+: HHS plans to open up billions in hospital Covid-19 grants in coming weeks
WASHINGTON — The Biden administration plans to open applications for billions of dollars in grants…
STAT+: Top Senate Democrat heads back to drawing board on drug pricing
WASHINGTON — A powerful Democratic committee chair is starting to work on a new drug…
Do public health officials need to be political activists? A fight over an HIV crisis renews the question
Most local health officials don’t accept their jobs expecting to be roped into political activism….
.jpg)
Door knocking works to get information to immigrant communities. Why aren’t more places using it for Covid-19?
WASHINGTON — Kica Matos wants to knock on every single door in her neighborhood. But…
STAT+: Worried drug pricing reform might be left behind, Democrat pushes Biden to make clear his support
WASHINGTON — At least one Democratic lawmaker is openly pushing President Biden to include drug…
Opinion: FTC’s challenge to Illumina’s vertical merger with Grail is all wrong
My mom died of stage 4 cancer in February 2008. Had the technology existed then…
STAT+: Biden officials met privately with 3M, AmerisourceBergen, PhRMA and more to debate shoring up the national stockpile
WASHINGTON — The Biden administration met privately this month with some of the nation’s biggest…
Opinion: STAT+: The FDA should embrace remote and automated drug inspection technology
While pharmaceutical regulatory authorities in other countries are employing creative ways like video-based remote inspections…
STAT+: The lobbying juggernaut the American Hospital Association is losing its top advocate at a critical moment for the industry
WASHINGTON — Tom Nickels helped build the American Hospital Association into one of the biggest…
STAT+: Hints emerge about a key Senate committee’s plans for health care
WASHINGTON — A Senate hearing Thursday provided one of the clearest roadmaps to date for…
Opinion: STAT+: Rethinking triage in an era of vaccine nationalism
Just about every schoolchild learns that Napoleon Bonaparte was a small man. But few know…
Opinion: Listen: Two addiction specialists debunk the myth of ‘excited delirium’ used in police encounters
In the tenth episode of “The First Opinion Podcast,” I talk with two physicians who…
STAT+: PhRMA chief talks strategy — and he’s surprisingly optimistic about drug pricing reform
WASHINGTON — Steve Ubl, who leads the drug industry lobbying powerhouse PhRMA, has a bold…
Opinion: STAT+: Three steps toward creating a functioning U.S. biosimilars market
The development of safe, effective, and innovative biologic medicines is one of modern medicine’s far-reaching…
.jpg)
Opinion: Make it easier for employers to help get America vaccinated
Businesses across the country are ready, willing, and able to help America get vaccinated. They…
Opinion: ‘It shouldn’t be this hard’ for foreign-trained health professionals to work in the U.S.
When people ask if they should call me “doctor,” I’ve always answered, “Please, call me…
Opinion: Listen: Antibiotic experts on the threat of antimicrobial resistant superbugs
This week’s “First Opinion Podcast” takes a look at antimicrobial resistance, a topic that should…
Opinion: India shouldn’t insist on ‘bridging trials’ in the middle of a pandemic
India is facing a brutal second wave of Covid-19, with daily case counts approaching 100,000….
STAT+: There’s no point person in Biden’s HHS for its $186 billion Covid-19 fund for health care providers
WASHINGTON — Health care providers are eagerly awaiting billions of dollars from a Covid-19 relief…
Opinion: Tax exemptions for nonprofit hospitals: It’s time taxpayers get their money’s worth
Many U.S. hospitals provide charity care to financially disadvantaged patients without the expectation of getting…
Opinion: ‘Authorization’ status is a red herring when it comes to mandating Covid-19 vaccination
Covid-19 vaccines offer a way out of the global crisis that has upended — and…
Opinion: Reforming and improving organ transplant systems will save lives, taxpayer dollars
Every day, 33 people — disproportionately people of color — die in the U.S. as…
Opinion: MAPGuide: A tool to help improve health-related public-private partnership agreements
Whenever a new infectious outbreak threatens global health, pharmaceutical companies, governments, international organizations, and philanthropies…